1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security |
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Stock Option (right to buy)
|
02/24/2011 |
02/24/2021 |
Common Stock
|
2,149
(4)
(5)
(6)
|
$
0.27
(7)
(8)
|
D
|
|
Stock Option (right to buy)
|
07/24/2009 |
07/24/2019 |
Common Stock
|
5,964
(6)
(9)
|
$
0.27
(7)
(8)
|
D
|
|
Stock Option (right to buy)
|
06/20/2011 |
06/20/2021 |
Common Stock
|
4,210
(5)
(6)
|
$
1.07
(7)
(8)
|
D
|
|
Stock Option (right to buy)
|
09/29/2011 |
09/29/2021 |
Common Stock
|
5,218
(5)
(6)
|
$
1.07
(7)
(8)
|
D
|
|
* |
If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** |
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) |
Pursuant to an Agreement and Plan of Merger, dated as of May 31, 2011, by and among LecTec Corporation ("LecTec"), Nerve Merger Sub Corp., a subsidiary of LecTec ("Merger Sub"), and AxoGen Corporation ("AC"), which the parties amended on June 30, 2011 and August 9, 2011 (as amended, the "Merger Agreement"), Merger Sub merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the "Merger"). The Merger was completed on September 30, 2011, and LecTec was renamed AxoGen, Inc. ("AxoGen"). In connection with the Merger, each share of AC common stock converted into 0.03727336 share of LecTec common stock at the effective time of the Merger. |
(2) |
Reflects 9,318 shares obtained as a result of an option exercise which was not reflected in orginal filing. |
(3) |
Shares are owned indirectly through Springboard Capital II, LLC. as a non-controlling limited partner. |
(4) |
9,318 shares under option were included in orginal filing but had previousely been exercised. |
(5) |
These options have not vested. |
(6) |
These shares vest annually over three years from grant date. |
(7) |
Amended to correct mistake in option exercise price after appropriate application of conversion ratio as explained in footnotes. |
(8) |
In connection with the Merger, each option to purchase shares of AC common stock was converted to an option to purchase 0.03727336 of a share of AxoGen common stock. |
(9) |
3,976 options have vested, and 1,988 options are unvested. |